Prothena's PRX012 granted FDA Fast Track designation for Alzheimer's treatment

PROTHENA CORP PUBLIC LTD CO

FDA Fast Track designation for PRX012, a next-generation anti-amyloid beta antibody for Alzheimer's.
PRX012 is currently in Phase 1 clinical study; designed for subcutaneous administration.
Fast Track may enable more frequent FDA interactions and eligibility for Accelerated Approval and Priority Review.
Prothena CEO Gene Kinney stated PRX012 has potential to lead a paradigm shift in Alzheimer's treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.